Clinical trials: Gastroesophageal Cancer
HER2-positive Locally Advanced Resectable Gastric Cancer
Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
This is a multicenter II study to compare KN026 and KN046 versus Oxaliplatin, Capecitabine combined KN026 and KN046 in patients with HER2-positive locally advanced resectable gastric cancer or gastroesophageal junction…
- Trial name
- NCT06023758
- Testing
- KN026, KN046, XELOX
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Peking University
Esophagogastric Cancer
A Study of Tooth Erosion in People With Esophagogastric Cancer
The researchers are doing this study to find out more about what may lead to the loss of tooth enamel (the thin outer covering of the tooth) and how often it happens in people with esophagogastric cancer, colorectal cancer…
- Trial name
- NCT05612048
- Testing
- Survey, Intra-oral camera, Optional Salvia sample
- Where
- United States
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastroesophageal Junction, Gastric / Gastroesophageal Junction Adenocarcinoma
Pucotenlimab Combined With Chemotherapy as Perioperative Treatment for Locally Advanced Gastroesophageal Junction Carcinoma
This study is a prospective, multicenter, single-arm clinical trial. The study intends to enroll patients with pathologically or cytologically confirmed resectable locally advanced gastroesophageal junction tumors (cT2N+M0 and…
- Conditions
- Gastroesophageal Junction, Gastric / Gastroesophageal Junction Adenocarcinoma, Neoadjuvant Chemoimmunotherapy, Adjuvant Therapy
- Trial name
- NCT07092449
- Testing
- Neoadjuvant chemo-immunotherapy
- Volunteers
- 30 people
- Sponsor
- Tang-Du Hospital
Stomach Neoplasms, Gastroesophageal Junction Neoplasms
ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction
That panitumumab in combination with Epirubicin, Cisplatin and Capecitabine (ECX) will safely decrease the frequency of pT3/T4 below that of ECX alone in subjects with locally advanced adenocarcinoma of the stomach and…
- Trial name
- NEOPECX (NCT01234324)
- Testing
- Epirubicin, Cisplatin, Capecitabine, Panitumumab, Epirubicin, Cisplatin, Capecitabine
- Where
- Germany
- Volunteers
- 171 people
- Sponsor
- AIO-Studien-gGmbH
Gastric Adenocarcinoma, Esophagus Adenocarcinoma
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer
Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5-fluorouracile (5-FU) in frail patients with advanced, recurrent or metastatic gastric, oesophageal or gastroesophageal junction cancer.
- Conditions
- Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- LOGICAN (NCT05476796)
- Testing
- Trifluridine/Tipiracil, Oxaliplatin, FOLFOX regimen
- Where
- 28 sites in France
- Volunteers
- 118 people
- Sponsor
- UNICANCER
Gastric Cancer
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or immunotherapy in…
- Trial name
- DG-03 (NCT04379596)
- Testing
- Fluorouracil (5-FU), Capecitabine, Durvalumab
- Where
- 71 sites in United States, Brazil and 12 more
- Volunteers
- 452 people
- Sponsor
- AstraZeneca
Gastric Cancer, Gastric Adenocarcinoma
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
This study is looking at how safe BHB810 is in adults with gastric and gastroesophageal adenocarcinoma (GEJ). The purpose of this study is also to look at: how well the study drug works, how the study drug moves into, through…
- Conditions
- Gastric Cancer, Gastric Adenocarcinoma, Gastric (Stomach) Cancer, Gastroesophageal Adenocarcinoma
- Trial name
- NCT07529808
- Testing
- BHB810
- Where
- 3 sites in United States
- Volunteers
- 164 people
- Sponsor
- BigHat Biosciences, Inc.
Adenocarcinoma of the Gastroesophageal Junction, Stage IIB Esophageal Adenocarcinoma
Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery
This randomized phase II trial studies how well regorafenib works in treating patients with cancer of the esophagus or gastroesophageal junction that has spread from where it started to nearby tissue or lymph nodes and have…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Stage IIB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma
- Trial name
- NCT02234180
- Testing
- Regorafenib
- Where
- 10 sites in United States
- Volunteers
- 3 people
- Sponsor
- Academic and Community Cancer Research United
Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach
Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach
The purpose of this study is to determine the rate of complete pathological responses (percentage of patients with pCR referring to the total number of enrolled and eligible patients), as evaluated centrally by a reference…
- Trial name
- HerFLOT (NCT01472029)
- Testing
- 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab, Post-operative treatment trastuzumab mono therapy
- Where
- Germany
- Volunteers
- 53 people
- Sponsor
- AIO-Studien-gGmbH
Barrett Esophagus, Esophageal Neoplasm
Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus
The purpose of this study is to determine if there are any early changes in DNA markers of blood and esophageal tissue in people with gastric reflux, Barrett's esophagus or esophageal cancer that can warn of a progression to…
- Conditions
- Barrett Esophagus, Esophageal Neoplasm, Gastroesophageal Reflux
- Trial name
- BE (NCT00431756)
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
The purpose of this study is to evaluate the efficacy and safety of perioperative Disitamab Vedotin plus Toripalimab and XELOX versus Disitamab Vedotin plus Toripalimab versus XELOX in subjects with HER2-expressing resectable…
- Trial name
- NCT06155383
- Testing
- Capecitabine, oxaliplatin, Disitamab Vedotin
- Where
- 11 sites in China
- Volunteers
- 90 people
- Sponsor
- RemeGen Co., Ltd.
Gastric Cancer, Adenocarcinoma of Esophagogastric Junction
TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma
This is a prospective one arm phase II clinical study to evaluate the efficacy and safety of TQB2450 (PD-L1 inhibitor), anlotinib combined with oxaliplatin and capecitabine in patients with unresectable locally advanced…
- Trial name
- NCT04891900
- Testing
- TQB2450/Anlotinib hydrochloride/Oxaliplatin/Capecitabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Henan Cancer Hospital
Melanoma, Non Small Cell Lung Cancer
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, High Grade Serous Adenocarcinoma of Ovary
- Trial name
- PRESERVE-009 (NCT05858736)
- Testing
- AI-061
- Where
- 5 sites in Australia
- Volunteers
- 18 people
- Sponsor
- OncoC4, Inc.
Gastroesophageal Junction, Gastroesophageal Adenocarcinoma
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, and HER3-DXD plus ramucirumab…
- Conditions
- Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
- Trial name
- NCT06445972
- Testing
- Ramucirumab, Paclitaxel, Sacituzumab Tirumotecan
- Where
- 46 sites in United States, Brazil and 9 more
- Volunteers
- 210 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Gastric Cancer, Advanced Gastroesophageal Junction Adenocarcinoma
Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC
At present, the treatment of advanced gastric/gastroesophageal junction cancer is a research hotspot in the academic community. In Asia, Siewert type II and type III are the main types of advanced gastric/gastroesophageal…
- Trial name
- NCT04890392
- Testing
- PD-1 inhibitor(Tislelizumab) ,SOX(S-1+ Oxaliplatin)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Gastric Cancer
Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer
The purpose of this study is to evaluate the efficacy and safety of Apatinib combined with S-1 as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma.
- Trial name
- NCT02525237
- Testing
- Apatinib, S-1
- Volunteers
- 30 people
- Sponsor
- Qingdao Municipal Hospital
Esophagus Cancer
Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer
In this phase I/II trial, we will evaluate a novel combination of chemotherapy, used concurrently with radiation therapy, in the preoperative therapy of locoregional carcinoma of the esophagus and gastroesophageal junction.
- Trial name
- NCT00193128
- Testing
- Oxaliplatin, Docetaxel, Capecitabine
- Where
- 7 sites in United States
- Volunteers
- 59 people
- Sponsor
- SCRI Development Innovations, LLC
Cancer, Tumor, Solid
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced…
- Conditions
- Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer
- Trial name
- NCT05620134
- Testing
- JK08, Pembrolizumab, Lenvatinib Pill
- Where
- 11 sites in Belgium, Spain
- Volunteers
- 263 people
- Sponsor
- Salubris Biotherapeutics Inc
Gastric Cancer, GastroEsophageal Cancer
A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer
The purpose of this trial is to estimate overall response rate (ORR) of SHR-1210 combined with capecitabine and oxaliplatin or with apatinib as first-line treatment in subjects with locally advanced or metastatic gastric or…
- Trial name
- NCT03472365
- Testing
- SHR-1210, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hypertension, Depression
Patient-Centred Innovations for Persons With Multimorbidity - Quebec
The aim of Patient-Centred Innovations for Persons With Multimorbidity (PACE in MM) study is to reorient the health care system from a single disease focus to a multimorbidity focus; centre on not only disease but also the…
- Conditions
- Hypertension, Depression, Anxiety, Musculoskeletal Pain
- Trial name
- PACEinMM-QC (NCT02789800)
- Testing
- DIMAC02
- Where
- 2 sites in Canada
- Volunteers
- 284 people
- Sponsor
- Université de Sherbrooke